Risk of development of hemorrhagic complications due to warfarin therapy

warfarin, hypocoagulation, haemorrhage

1. Задионченко В. С., Шехян Г. Г., Щикота А. М., Ялымов А. А. Место Варфарина в лечении и профилактике тромбоэмболий // Российский медицинский журнал. 2011. № 26. С. 1648- 1651.

2. Румянцев Н. А., Сычёв Д. А., Кукес В. Г. Перспективы индивидуализации применения и дозирования пероральных антикоагулянтов и статинов у пациентов в рутинной клинической практике // Клин. фармакол. и терапия. 2015. Т. 96, № 6. С. 1065-1068.

3. Шевела А. И., Лифшиц Г. И., Новикова Я. В., Севостьянова К. С. Фармакогенетические основы применения варфарина // Флебология. 2008. № 3. С. 35-37.

4. Anderson J. L., Horne B. D., Stevens S. M. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation // Circulation. 2007. Vol. 116. P. 2563- 2570.

5. Baker W. L., Johnson S.l. G Pharmacogenetics and oral anti-thrombotic drugs // Current Opinion in Pharmacology. 2016. Vol. 27. P. 38-42.

6. Beyth R. J., Quinn L. M., Landefeld C. S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin // Amer. J. Med. 1998. Vol. 105, № 2. P. 91-99.

7. Bloomfield H. E., Taylor B. C., Krause A. et al. Safe and effective anticoagulation in the outpatient setting : a systematic review of the evidence. VA Evidence-based Synthesis Program (ESP) Medical CenterWashington (DC) : Department of Veterans Affairs (US). Washington, 2011.P. 20

8. Bodin L., Verstuyft C., Tregouet D. A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity // Blood. 2005. Vol. 106, № 1. P. 135-140.

9. Burmester J. K., Berg R. L., Yale S. H. et al. A randomized controlled trial of genotype-based Coumadin initiation // Genet Med. 2011. Vol. 13. P. 509-518.

10. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the еfficacy and safety of anticoagulation: a prospective randomized controlled study // Clin. Pharmacol. Ther. 2008. Vol. 83. P. 460-470.

11. Crespi C., Miller V. The R144C change in the CYP2C9*2 allele alters interaction of the cytochromeP450 with NADPH: cytochrome P450 oxidoreductase // Pharmacogenetics. 1997. Vol. 7. P. 203-210.

12. Donze´ J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy // Amer. J. Med. 2012. Vol. 125, № 8. P. 773-778.

13. Fang M. C., Go A. S., Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages // Amer. J. Med. 2007. Vol. 120, № 8. P. 700-705.

14. Fang M. C., Go A. S., Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study // J. Am. Coll Cardiol. 2011. Vol. 58. P. 395-401.

15. Fang M. C., Go A. S., Hylek E. M. et al. Age and the risk of war-fa rin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study // J. Am. Geriatr. Soc. 2006. Vol. 54. P. 1231-1236.

16. Gomberg-Maitland M., Wenger N. K., Feyzi J. et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials // Eur. Heart J. 2006. Vol. 27, № 16. P. 1947-1953.

17. Haining R., Hunter A., Veronese M. et al. Allelic variants of human cytochrome P4502C9 : baculovirus-mediated expression purification,structural characterisation, substrate streoselectivity and prochiral selectivity of the wild-type and I359L mutant forms // Arch. Biochem. Biophys. 1996. Vol. 333, № 2. P. 447-458.

18. Higashi M. K., Veenstra D. L., Kondo L. M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy // J. A. M. A. 2002. Vol. 287, № 13. P. 1690-1698.

19. Holbrook A. M., Pereira J. A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions // Arch. Intern. Med. 2005. Vol. 165, № 10. P. 1095-1106.

20. Kamali F., Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy // Brit. J. Clin. Pharmacol. 2006. Vol. 61, № 6. Р. 746-751.

21. Kimmel S. E., French B., Kasner S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing // N. Engl. J. Med. 2013. Vol. 369, № 24. P. 2283-2293.

22. Limdi N. A., McGwin G., Goldstein J. A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin // Clin. Pharmacol. Ther. 2008. Vol. 83, № 2. P. 312-321.

23. Lind M., Boman K., Johansson L. et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment // Arch. Intern. Med. 2009. Vol. 169, № 13. P. 1210-1215.

24. Lindh J. D., Holm L., Dahl M. L. et al. Incidence and predictors of severe bleeding during warfarin treatment // J. Thromb. Thrombolysis. 2008. Vol. 5, № 2. P. 151-159.

25. Lip G. Y., Frison L., Halperin J. L. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score // J. Am. Coll. Cardiol. 2011. Vol. 57, № 2. P. 173-180.

26. McMahan D. A., Smith D. M., Carey M. A. et al. Risk of major hemorrhage for outpatients treated with warfarin // J. Gen. Intern. Med. 1998. Vol. 13. P. 311-316.

27. Meckley L. M., Wittkowsky A. K., Rieder M. J. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients // Thromb. Haemost. 2008. Vol. 100, № 2. P. 229-239.

28. Mohamed H. A., Johnson S. J., Johnson A. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? // Curr. Opin. Cardiol. 2013. Vol. 28, № 3. P. 305-314.

29. Moyer T. P., O’Kane D. J., Linnea M. et al. Warfarin sensitivity genotyping : a review of the literature and summary of patient experience // Mayo Clin. Proc. 2009. Vol. 84, № 12. P. 1079-1094.

30. Patrick A. R., Avorn J., Choudhry N. K. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation // Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2. P. 429-436.

31. Pink J., Pirmohamed M., Lane S. et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation // Clin. Pharmacol. Ther. 2014. Vol. 95. P. 199-207.

32. Roth J. A., Bradley K., Thummel K. E. et al. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting // Pharmacoepidemiol. Drug. Saf. 2015. Vol. 24, № 6. P. 619-627.

33. Schalekamp T., Brassé B. P., Roijers J. F. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation // Clin. Pharmacol. Ther. 2006. Vol. 80. P. 13-22

34. Schauer D. P., Moomaw C. J., Wess M. et al. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin // J. Gen. Intern. Med. 2005. Vol. 20, № 12. P. 1114-1119.

35. Shireman T.I., Mahnken J. D., Howard P.A. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients // Chest. 2006. Vol. 130, № 5. P. 1390-1396.

36. Singer D. E., Chang Y., Fang M. C. et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study// Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2, № 4. P. 297-304.

37. Suzuki S., Yamashita T., Kato T. et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation // Circ. J. 2007. Vol. 71. P. 761-765.

38. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment // Blood. 2000. Vol. 96, № 5. P. 1816-1819.

39. Wang M., Lang X., Cui S. et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial // Int. J. Med. Sci. 2012. Vol. 9. P. 472-479.

40. Wynne H. et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements // Brit. J. Clin. Pharmacol. 1995. Vol. 40. P. 203-207.

41. Wysowski D. K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action // Arch. Intern. Med. 2007. Vol. 167. P. 1414-1419.

42. Yang J., Chen Y., Li X. et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis // Int. J. Cardiol. 2013. Vol. 168. P. 4234-4243.